DNA methyltransferase 3a hot-spot locus is not mutated in pediatric patients affected by acute myeloid or T cell acute lymphobla stic leukemia: an Italian study confirming a mutational rate similar to that previously described. 3 All three mutations occurred at aminoacid R882: two patients had R882H mutation, while one patient carried the mutation R882P.
These mutated sequences were present with mean frequencies of 46.16 ± 2.9 %, indicating the heterozygous status of the mutation.
Our results confirmed that also in the Italian pediatric AML patients DNMT3A mutations at R882 locus are rare; moreover, we highlighted that DNMT3A is not mutated also in pediatric T-ALL. We enhanced mutational analysis of methyltransferases by sequencing DNMT3B, also a member of the DNMT3 family of genes. 5, 11 DNMT3B is considered functionally complementary to DNMT3A with common and differential target specificities, and may be considered to play a role in the aberrant methylation observed in acute leukemia. 12 The mutational screening was performed in part of the pediatric cohort here presented. In particular, in 60 T-ALL patients and 90 AML patients were sequenced at the homolog aminoacid R823 at exon 23 of DNMT3B and never found mutated, suggesting that both methylases are not informative for pediatric leukemia at the focused genomic locus.
Specifically, the difference between genetic alterations observed in childhood leukemia with respect to adults confirmed that only in few cases genes found to be mutated from adult wholegenome sequencing are relevant for childhood AML. It is to be expected that other genes more essential for the pathogenesis of childhood leukemia, and most likely of other pediatric solid tumours, will be discovered in extended somatic whole-genome sequencing of pediatric specimens of diseased cells. This study also highlights how recent improvements in sequencing and bioinformatics technologies provide new, rapid and extremely informative methods to study the mutation status of genes in large cohorts of patients. This opportunity to genetically characterize patients opens a new era, where discovery of specific lesions might improve knowledge on leukemogenesis and permit to therapeutically target specific gene lesions.
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